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Abstract Statins are hypolipidemic drugs which not only
improve cholesterol but also triglyceride levels. Whereas their
cholesterol-reducing effect involves inhibition of de novo
biosynthesis of cellular cholesterol through competitive inhibition
of its rate-limiting enzyme 3-hydroxy-3-methylglutaryl CoA
reductase, the mechanism by which they lower triglycerides
remains unknown and forms the subject of the current study.
Treatment of normal rats for 4 days with simvastatin decreased
serum triglycerides significantly, whereas it increased high
density lipoprotein cholesterol moderately. The decrease in
triglyceride concentrations after simvastatin was caused by a
reduction in the amount of very low density lipoprotein particles
which were of an unchanged lipid composition. Simvastatin
administration increased the lipoprotein lipase mRNA and
activity in adipose tissue and heart. This effect on lipoprotein
lipase was accompanied by decreased mRNA as well as plasma
levels of the lipoprotein lipase inhibitor apolipoprotein C-III.
These results suggest that the triglyceride-lowering effect of
statins involves a stimulation of lipoprotein lipase-mediated
clearance of triglyceride-rich lipoproteins.
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1. Introduction
Intracellular cholesterol levels are tightly maintained within
a narrow concentration range by an intricate transcriptional
control mechanism, which involves the sterol response element
binding proteins (SREBPs) of the helix-loop-helix transcrip-
tion factor family [1]. Three distinct SREBPs have been iden-
ti¢ed, designated SREBP-1a and SREBP-1c, derived from the
SREBP-1 gene, and SREBP-2, which is encoded by an inde-
pendent gene. A homologue of SREBP, termed adipocyte
determination and di¡erentiation factor-1 (ADD-1) was inde-
pendently cloned and characterized as implicated in adipocyte
di¡erentiation [2]. SREBPs are synthesized as membrane-
bound precursors that are localized on the nuclear envelope
and the endoplasmic reticulum and become proteolytically
activated as the concentration of intracellular sterols de-
creases. The activated SREBP is subsequently targeted to
the nucleus where it transactivates genes involved in the chol-
esterol synthesis and uptake. These genes include the ones
encoding 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) syn-
thase, the low density lipoprotein (LDL) receptor, HMG-CoA
reductase, farnesyl diphosphate synthase and squalene syn-
thase [3^8]. Interestingly, SREBP also controls the expression
of certain genes involved in fatty acid metabolism, such as
acetyl CoA carboxylase [9,10], fatty acid synthase [10^12]
and stearoyl-CoA desaturase [13].
SREBPs are not only important for intracellular cholesterol
homeostasis, but they also play a role in controlling plasma
cholesterol. In fact, the most e¡ective therapy for hyperchol-
esterolemia, a condition associated with atherosclerotic vascu-
lar disease, currently consists of the administration of statin
lipid-lowering drugs. These compounds block the rate-limiting
enzyme of the endogenous cholesterol biosynthesis pathway,
HMG-CoA reductase, through competitive inhibition. The
resulting decrease in the cellular cholesterol content will sub-
sequently lead to the activation of the SREBPs and the in-
duction of downstream target genes, such as the LDL recep-
tor. On a whole organism level, enhanced LDL receptor
clearance will ultimately translate in a signi¢cant reduction
in circulating cholesterol levels. This reduction in cholesterol
levels is often associated with a decrease in triglyceride levels.
The aim of the present study was to analyze the mechanisms
by which statins achieve this triglyceride-lowering e¡ect. Our
results obtained with simvastatin in a rat model demonstrate
an important decrease in serum triglyceride-rich lipoproteins
without a major e¡ect on high density lipoprotein (HDL)
concentrations. This action of simvastatin is mediated by
both a decrease in apolipoprotein C-III levels in liver and
plasma and a stimulation of lipoprotein lipase (LPL)
mRNA and activity levels in heart and adipose tissue, provid-
ing a mechanistic basis for its triglyceride-lowering e¡ect.
2. Materials and methods
2.1. Materials
Simvastatin was kindly provided by Dr S. Wright from Merck
(Rahway, NJ, USA). Carboxymethylcellulose was purchased from
Serva (Heidelberg, Germany).
2.2. Animals
10 Weeks old male Sprague-Dawley rats were randomized to treat-
ment groups and treated daily by oral gavage with simvastatin sus-
pended in 1% carboxymethylcellulose at the indicated period of time
and doses. Control animals received an equal volume (5 ml/kg/day) of
carboxymethylcellulose solution. At the end of the experiments, ani-
mals were weighed and killed by exsanguination while under ether
anesthesia. Blood was collected and serum was separated and used
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within 1 week for analysis of lipids, lipoproteins and apolipoproteins.
Metabolic active tissues, such as liver, muscle, heart and omental fat
pads, were removed, weighed and frozen in liquid nitrogen.
2.3. Serum lipid, apolipoprotein and lipoprotein measurements
Serum and lipoprotein lipid (total cholesterol, triglyceride and
phospholipid) concentrations were determined by enzymatic assays
adapted to microtiter plates using commercially available reagents
(Boehringer Mannheim, Germany: for cholesterol and triglycerides;
Biomerieux, Marcy l’Etoile, France: for phospholipids). The serum
HDL cholesterol content was determined after precipitation of apoli-
poprotein (apo) B-containing lipoproteins with phosphotungstic acid/
Mg (Boehringer Mannheim). Non-HDL cholesterol was calculated as
the di¡erence between the total and HDL cholesterol. Serum levels of
rat apo A-I and apo A-II were measured by an immunonephelometric
assay using speci¢c polyclonal antibodies. Interassay coe⁄cients of
variation for lipids and apolipoproteins ranged from 1.5% to 5.3%.
The lipoprotein fractions (VLDL+IDL, d = 1.006^1.019 g/ml; LDL,
d = 1.019^1.063 g/ml; HDL2, d = 1.063^1.12 g/ml; HDL3, d = 1.12^
1.21 g/ml) were isolated by sequential ultracentrifugation of pooled
rat serum [14]. Each fraction was further puri¢ed by a second ultra-
centrifugation at the same density intervals before analysis. After ex-
tensive dialysis at 4‡C against 10 mM phosphate-bu¡ered saline (PBS)
at pH 7.2 containing 10 Wmol/l EDTA, the protein concentration of
each lipoprotein fraction was determined by the method of Lowry et
al. [15]. For fast protein liquid chromatography (FPLC) size fraction-
ation of lipoproteins, 300 Wl of serum isolated from individual rats
was injected on a Sepharose 6HR 10/30 pre-packed column (Pharma-
cia, Uppsala, Sweden) and eluted at a constant £ow rate of 0.2 ml/min
with PBS pH 7.2. The e¥uent was monitored at 280 nm, collected in
0.3 ml fractions and cholesterol concentrations were determined in
0.1 ml of each fraction. The apolipoprotein composition of isolated
lipoproteins was analyzed by polyacrylamide gradient (4^20%) gel
electrophoresis in the presence of SDS (SDS-PAGE) using ready to
use materials (Novex, San Diego, CA, USA). 15 Wg of proteins of
each lipoprotein fraction was loaded on the gels. Electrophoresis was
performed in 0.025 M Tris, 0.192 M glycine, SDS 0.1%, pH 8.3. The
apolipoproteins were identi¢ed by their molecular weight determined
by the simultaneous migration of standards of a known molecular
weight (Low Molecular Weight markers electrophoresis calibration
kit, Pharmacia Biotech, Uppsala, Sweden).
2.4. Measurement of tissue LPL activity
LPL enzymatic activity was measured in extracts from heart, muscle
and omental adipose tissue according to the procedure of Ramirez
[16] with minor modi¢cations. The assay mixture contained 0.6 mM
glycerol tri[9,10-(n)-3H]oleate (12 Ci/mol), 50 mM MgCl2, 0,05% fatty
acid-free BSA, 3% rat serum (pre-heated 30 min at 56‡C), 25 mM
PIPES (pH 7.5) and 0.02 ml of sample in a ¢nal volume of 0.2 ml. The
reaction was stopped and [3H]oleate separated from substrate was
quanti¢ed. One unit of enzyme activity was de¢ned as the amount
of enzyme which releases 1 Wmol oleate/min at 25‡C.
2.5. RNA analysis
RNA was isolated from liver, heart, muscle and omental adipose
tissue by the acid guanidinium thiocyanate/phenol/chloroform method
[17]. Northern blot analysis of total cellular RNA was performed as
described [18]. Rat apo A-I, apo A-II, apo C-III and human LPL
cDNA clones were used as probes. The cDNA clone 36B4 encoding
the human acidic ribosomal phosphoprotein PO [19] was used as a
control probe. All probes were labelled by random-primed labelling
(Boehringer Mannheim). Filters were hybridized to 1U106 cpm/ml of
each probe. They were washed once in 500 ml 75 mmol/l NaCl,
7.5 mmol/l sodium citrate and 0.1% SDS for 10 min at 20‡C and
twice for 30 min at 65‡C and subsequently exposed to X-ray ¢lm
(X-OMAT-AR, Kodak). Autoradiograms were analyzed by quantita-
tive scanning densitometry (Bio-Rad GS670 Densitometer, Bio-Rad
Laboratories, CA, USA) as described [18].
3. Results and discussion
In order to study the e¡ects of statins on serum lipids and
lipoproteins, rats were initially treated with simvastatin at a
dose corresponding to 120 mg/kg/day. Administration of sim-
vastatin by oral gavage for 4 days did not change body
weights (473 þ 35 g in control animals versus 462 þ 35 g in
simvastatin treated animals). Although serum total cholesterol
levels had a tendency to increase in treated rats, no statisti-
cally signi¢cant di¡erence with the control animals could be
observed. The repartition of cholesterol among the lipopro-
teins showed slight di¡erences and treated rats displayed high-
er HDL cholesterol levels (P6 0.05) and lower non-HDL chol-
esterol concentrations than control animals (Table 1). The
cholesterol pro¢les obtained by gel ¢ltration chromatography
are depicted in Fig. 1 and con¢rm the slight increase of HDL
cholesterol levels in simvastatin-treated rats measured by the
precipitation technique. More particularly, a shift towards
larger-sized HDL particles is observed in treated rats. This
observation is concordant with the reduction of apo A-I
and apo A-II observed in treated rats (Table 1), indicating
that administration of simvastatin to rats leads to a more
pronounced accumulation of cholesterol-enriched and less
dense HDL particles looking like the HDL2 subspecies. These
¢ndings con¢rm previous observations of poor cholesterol-
Fig. 1. E¡ects of simvastatin on serum lipoproteins. A representa-
tive pro¢le of the serum cholesterol distribution between lipopro-
teins from adult male rats treated for 4 days with simvastatin (SIM)
at a dose of 120 mg/kg/day or vehicle only (CON) is shown. Equal
volumes of serum from control and simvastatin-treated rats were
separated by gel ¢ltration chromatography and cholesterol concen-
trations were measured in the isolated fractions as indicated under
Section 2. Elution patterns of VLDL, IDL, LDL and HDL lipopro-
teins are indicated.
Table 1
The in£uence of simvastatin on serum lipid concentrations and apo A-I and apo A-II levels in rats
Dose
(mg/kg/day)
Total cholesterol
(mg/dl)
HDL Chol
(mg/dl)
Non-HDL
cholesterol (mg/dl)
TG
(mg/dl)
Apo A-I
(mg/dl)
Apo A-II
(mg/dl)
0 65 þ 10 47 þ 8 19 þ 5 166 þ 39 55 þ 6 26 þ 5
120 80 þ 6 64 þ 3* 17 þ 8 95 þ 16* 50 þ 7 23 þ 5
Adult male rats (n = 4/group) received simvastatin intragastrically at the indicated dose for 4 days. Serum total, HDL cholesterol, triglyceride
(TG), apo A-I and apo A-II concentrations were measured as described in Section 2. Statistically signi¢cant di¡erences (U Mann-Whitney,
P6 0.05) between control and simvastatin-treated animals are indicated by an asterisk.
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lowering by statins in rodents, an e¡ect mainly attributed to
an increased hepatic induction of the HMG-CoA reductase
mass and activity that compensates for the enzymatic inhib-
itory e¡ect of simvastatin [20^22]. Despite the absence of a
signi¢cant cholesterol-lowering e¡ect of simvastatin in rats,
which is in sharp contrast to the situation observed in man
and other animal models, our results unequivocally show that
treatment of normal rats with simvastatin results in a major
decrease in serum triglyceride concentrations (Table 1), attrib-
uted essentially to a robust decrease in VLDL concentrations
in serum (Fig. 1). In addition, a moderate decrease in IDL
was observed in treated rats whereas the LDL fraction was
slightly increased (Fig. 1). To analyze whether the e¡ects of
simvastatin on the lipoprotein levels of treated rats (i.e. a
slight increase in HDL and LDL, a moderate decrease in
IDL and a strong reduction of VLDL) were associated with
alterations in the biochemical composition of the lipoprotein
fractions, lipoproteins were isolated by sequential ultracentri-
fugation and their chemical composition determined (Fig. 2).
Compared to control rats, particles £otating between 1.006
and 1.019 (VLDL+IDL) isolated from rats treated with sim-
vastatin displayed basically a similar pattern with an un-
changed protein and cholesterol composition and minor var-
iations regarding the triglyceride and phospholipid content,
indicating therefore that the decrease in triglyceride concen-
trations observed in treated rats is rather due to a decrease in
the amount of lipid particles than to changes in the lipid
composition. In contrast, the relative triglyceride content of
particles in the LDL density range (1.019^1.063) decreased by
27% after simvastatin (Fig. 2). The relative decrease in the
triglyceride content of the LDL particles was compensated
by an enrichment in phospholipids and, to a lesser extent, in
proteins (Fig. 2). These relative changes in LDL composition
after simvastatin treatment are indicative of an increased lip-
olysis of triglycerides in plasma lipoproteins leading to an
accelerated conversion into LDL particles, which is consistent
with the cholesterol pro¢le of the di¡erent lipoprotein frac-
tions outlined in Fig. 1. Finally, the overall composition of
HDL, isolated as particles in the 1.063^1.12 (HDL2) and in
the 1.12^1.21 (HDL3) density range, was not signi¢cantly af-
fected by simvastatin treatment (Fig. 2), reinforcing the hy-
pothesis that, most likely, the number of HDL2 particles is
increased in simvastatin-treated animals.
In order to de¢ne the mechanism by which simvastatin
a¡ects the lipid and lipoprotein metabolism, we studied its
e¡ect on some key apolipoproteins and lipases involved in
triglyceride metabolism, such as apo C-III, LPL and hepatic
lipase (HL). Whereas LPL and HL promote the hydrolysis
and removal of triglyceride-rich lipoproteins from plasma,
apo C-III antagonizes the clearance of triglycerides by inhib-
iting the plasma LPL activity. Therefore, the apolipoprotein
composition of the di¡erent lipoprotein fractions was ¢rst
Fig. 2. Adult male rats (n = 4/group) were treated intragastrically with simvastatin at a dosis of 120 mg/kg/day for 4 days. Serum lipoproteins
VLDL+IDL, LDL, HDL2 and HDL3 were isolated by sequential density ultracentrifugation at the indicated density intervals and lipoprotein
total cholesterol, triglyceride, phospholipid and protein concentrations were measured and expressed as percentage of the total as described in
Section 2.
Fig. 3. The in£uence of simvastatin treatment on the apolipoprotein
composition of serum lipoproteins. Rats were treated daily for
4 days with simvastatin (S) at a dosis of 120 mg/kg/day or vehicle
only (C). Serum was pooled (n = 4/treatment group), lipoproteins
were isolated by sequential ultracentrifugation and the apolipopro-
tein composition was analyzed by non-reducing SDS-PAGE as de-
scribed under Section 2.
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analyzed by SDS-PAGE. Compared to control, treatment
with simvastatin did induce a drastic decrease in the apo Cs
and apo E content in VLDL-IDL particles (Fig. 3, lane 1
versus lane 2). In contrast, the apolipoprotein distribution in
LDL, HDL2 and HDL3 was not really a¡ected by simvastatin
treatment, except for a slight increase of the apo E content in
the HDL2 particles derived from treated rats (Fig. 3, lanes 5
and 7 versus lanes 6 and 8, respectively). Since apo C-III is a
major determinant of serum triglyceride levels [23,24], we next
determined the steady state levels of its mRNA in the liver of
control and treated animals. Consistent with the decreased
apo C-III protein content in the VLDL-IDL fraction in
treated rats, administration of simvastatin reduced also apo
C-III mRNA levels by 30% compared to control animals
(P = 0.08; Fig. 4A). The reducing e¡ect of simvastatin on
apo C-III mRNA expression was even more pronounced (ap-
proximately 70%) when rats were treated at a dose of 250 mg/
kg/day (Fig. 4A). The decrease of apo C-III mRNA expres-
sion seemed speci¢c, since no signi¢cant changes in liver HL,
apo A-I, and A-II mRNA levels were observed (Fig. 4B).
In adipose tissue, treatment with simvastatin increased LPL
mRNA levels by 2-fold in comparison to controls (Fig. 5A),
although no statistically signi¢cance could be reached. This
increase in LPL gene expression after simvastatin was paral-
leled by a comparable statistically signi¢cant increase in adi-
pose tissue LPL activity (2-fold increase; P6 0.01; Fig. 5B).
In heart, comparable increases in LPL mRNA and activity
were detected (Fig. 5A and B). Interestingly, LPL mRNA
and activity levels in skeletal muscle, another site of LPL
production, did not change after simvastatin treatment (Fig.
5A and B). These observations in rat of an enhanced LPL
activity in heart and adipose tissue together with the observed
shift towards HDL2 particles after simvastatin treatment are
in agreement with previous studies in man demonstrating a
positive correlation between HDL2 levels and the LPL activity
or triglyceride clearance rate (for review, see [25]).
One potential candidate involved in translating the e¡ects
of simvastatin on gene expression is the SREBP family of
transcription factors, which have been shown to become pro-
teolytically activated by reduced intracellular cholesterol levels
after HMG-CoA reductase inhibitors (see Section 1). Consis-
tent with a role for SREBP in controlling LPL expression, it
was recently shown that LPL mRNA levels were induced by
ectopic overexpression of SREBP [10,12]. Furthermore, we
recently identi¢ed a functional sterol responsive element for
SREBP in the human LPL promoter (unpublished data). In
contrast to the regulatory e¡ects on LPL, which are most
likely mediated via interaction of the SREBPs with the LPL
promoter, it is at present unclear how simvastatin a¡ects apo
C-III expression. Studies addressing this issue are currently
underway in our laboratory.
Altogether, our data suggest that in a rat model, simvasta-
Fig. 4. The in£uence of simvastatin treatment on liver apo C-III (A), apo A-I, apo A-II and HL mRNA levels (B). (A) Rats (n = 4/group) were
treated for 4 days with simvastatin at two di¡erent doses corresponding to 120 mg/kg/day and 250 mg/kg/day. Liver apo C-III mRNA levels
were measured at the end of the treatment period as described in Section 2. RNA values are expressed in relative absorbance units (R.A.U.)
taking the control values as 100%. Statistically signi¢cant di¡erences (P6 0.05 with the U Mann-Whitney test) are indicated by an asterisk.
(B) Liver RNA samples from controls and rats treated for 4 days with simvastatin at a dosis corresponding to 120 mg/kg/day were blotted on
a nylon membrane and hybridized to apo A-I, apo A-II, HL and 36B4 cDNAs.
Fig. 5. The in£uence of simvastatin treatment on LPL mRNA levels
(A) and activity (B) in rat adipose tissue, heart and skeletal muscle.
(A) Adult male rats were treated daily for 4 days with simvastatin
at a dosis of 120 mg/kg/day. Total RNA was extracted and LPL
and 36B4 mRNA levels were measured as described in Section 2.
LPL mRNA values (mean þ S.D.) are expressed relative to 36B4
mRNA levels and represented in relative absorbance units (R.A.U.).
(B) Tissue LPL activity was measured as described in Section 2.
Statistically signi¢cant di¡erences (P6 0.01, U Mann-Whitney test)
are indicated by two asterisks.
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tin increases lipolysis of triglycerides rather than causing a
reduction in hepatic VLDL production. This is in contrast
to the triglyceride-lowering induced by activators of the per-
oxisome proliferator-activated receptor (PPAR) K, such as
¢brates, which in general is associated with a reduced hepatic
VLDL secretion [26^29]. Furthermore, ¢brate treatment does
not change the lipid composition of LDL lipoproteins (data
not shown), suggesting that these drugs have rather minor
e¡ects on VLDL lipolysis. The triglyceride-reducing e¡ect of
statins appears therefore more similar to the e¡ects observed
with thiazolidinedione PPARQ agonists, which in contrast to
PPARK agonists, mainly a¡ect the peripheral LPL-mediated
lipolysis of triglycerides. These di¡erences are indicatives that
the same triglyceride-lowering e¡ect of di¡erent lipid-lowering
agents, such as ¢brates, thiazolidinediones and statins, are
achieved through distinct mechanisms.
The statins currently form the cornerstone for the clinical
management of hypercholesterolemia. Administration of these
drugs to subjects with hypercholesterolemia results in a sig-
ni¢cant reduction of cardiovascular events and a decrease in
mortality [30]. The present data obtained in a rat model
underscore the fact that these compounds not only lower chol-
esterol levels, but also signi¢cantly reduce the concentration
of triglycerides, through an LPL-mediated clearance of tri-
glyceride-rich lipoproteins. It is very likely that the combina-
tion of cholesterol-lowering with triglyceride-lowering under-
lies the remarkable e⁄cacy of statins in subjects with
combined hyperlipidemia syndromes, as often seen in obesity
and type 2 diabetes mellitus [31]. Consistent with this hypoth-
esis, subjects with type 2 diabetes would bene¢t most from
intervention with this class of drugs.
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